The primary glomerulonephritides: A systems biology approach

Nature Reviews Nephrology

Volumn 9, Issue 9, 2013, Pages 500-512

  Jiang, Song ^a   Chuang, Peter Y ^b   Liu, Zhi Hong ^a   He, John C ^b  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; COMPLEMENT FACTOR H; HOMEODOMAIN INTERACTING PROTEIN KINASE 2; IMMUNOSUPPRESSIVE AGENT; MESSENGER RNA; MICRORNA; MICRORNA 200A; MICRORNA 200B; MICRORNA 429; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RIBOSOME RNA; SOMATOMEDIN BINDING PROTEIN 1; STEROID; TRANSFER RNA; UNCLASSIFIED DRUG; UNTRANSLATED RNA; WNT PROTEIN;

AFRICAN AMERICAN; DNA SEQUENCE; FOCAL GLOMERULOSCLEROSIS; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENE PRODUCT; GENETIC ASSOCIATION; GENOMICS; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HEYMANN NEPHRITIS; HIGH THROUGHPUT SEQUENCING; HISTOPATHOLOGY; HIV ASSOCIATED NEPHROPATHY; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; KIDNEY PARENCHYMA; MEMBRANOUS GLOMERULONEPHRITIS; METABOLOMICS; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMS BIOLOGY; TRANSCRIPTOMICS;

ANIMALS; GENE EXPRESSION PROFILING; GENOME-WIDE ASSOCIATION STUDY; GLOMERULONEPHRITIS; HUMANS; KIDNEY; MODELS, BIOLOGICAL; SYSTEMS BIOLOGY;

EID: 84883175724     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2013.129     Document Type: Review

References (80)

1. United States Renal Data System. 2012 Atlas of CKD and ESRD [online], http://www.usrds.org/atlas.aspx (2012).
2. Zuo, L. & Wang, M. Current burden and probable increasing incidence of ESRD in China. Clin. Nephrol. 74 (Suppl. 1), S20-S22 (2010).
3. Greenbaum, L. A., Benndorf, R. & Smoyer, W. E. Childhood nephrotic syndrome-current and future therapies. Nat. Rev. Nephrol. 8, 445-458 (2012).
4. He, J. C., Chuang, P. Y., Ma'ayan, A. & Iyengar, R. Systems biology of kidney diseases. Kidney Int. 81, 22-39 (2012).
5. Keller, B. J., Martini, S., Sedor, J. R. & Kretzler, M. A systems view of genetics in chronic kidney disease. Kidney Int. 81, 14-21 (2012).
6. Komorowsky, C. V., Brosius, F. C. 3rd, Pennathur, S. & Kretzler, M. Perspectives on systems biology applications in diabetic kidney disease. J. Cardiovasc. Transl. Res. 5, 491-508 (2012).
7. Jim, B., Santos, J., Spath, F. & Cijiang He, J. Biomarkers of diabetic nephropathy, the present and the future. Curr. Diabetes Rev. 8, 317-328 (2012).
8. Starkey, J. M. & Tilton, R. G. Proteomics and systems biology for understanding diabetic nephropathy. J. Cardiovasc. Transl. Res. 5, 479-490 (2012).
9. Hildebrandt, F. Genetic kidney diseases. Lancet 375, 1287-1295 (2010).
10. Heeringa, S. F. et al. COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness. J. Clin. Invest. 121, 2013-2024 (2011).
11. Mele, C. et al. MYO1E mutations and childhood familial focal segmental glomerulosclerosis. N. Engl. J. Med. 365, 295-306 (2011).
12. Sanna-Cherchi, S. et al. Exome sequencing identified MYO1E and NEIL1 as candidate genes for human autosomal recessive steroid-resistant nephrotic syndrome. Kidney Int. 80, 389-396 (2011).
13. De Spiegelaere, W. et al. Quantitative mRNA expression analysis in kidney glomeruli using microdissection techniques. Histol. Histopathol. 26, 267-275 (2011).
14. Cohen, C. D., Frach, K., Schlondorff, D. & Kretzler, M. Quantitative gene expression analysis in renal biopsies: a novel protocol for a high-throughput multicenter application. Kidney Int. 61, 133-140 (2002).
15. Gadegbeku, C. A. et al. Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int. 83, 749-756 (2013).
16. Compendia Bioscience & Personalized Molecular Nephrology Research Laboratory. Nephromine [online], http://www.nephromine.org (2012).
17. Zurbig, P. et al. Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes 61, 3304-3313 (2012).
18. Mullen, W., Delles, C. & Mischak, H. Urinary proteomics in the assessment of chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 20, 654-661 (2011).
19. Thongboonkerd, V. Biomarker discovery in glomerular diseases using urinary proteomics. Proteomics Clin. Appl. 2, 1413-1421 (2008).
20. Portilla, D., Schnackenberg, L. & Beger, R. D. Metabolomics as an extension of proteomic analysis: study of acute kidney injury. Semin. Nephrol. 27, 609-620 (2007).
21. Wishart, D. S. Metabolomics: a complementary tool in renal transplantation. Contrib. Nephrol. 160, 76-87 (2008).
22. Hirayama, A. et al. Metabolic profiling reveals new serum biomarkers for differentiating diabetic nephropathy. Anal. Bioanal. Chem. 404, 3101-3109 (2012).
23. Donovan, M. J., Costa, J. & Cordon-Cardo, C. Systems pathology: a paradigm shift in the practice of diagnostic and predictive pathology. Cancer 115, 3078-3084 (2009).
24. Lai, K. N. Pathogenesis of IgA nephropathy. Nat. Rev. Nephrol. 8, 275-283 (2012).
25. Feehally, J. et al. HLA has strongest association with IgA nephropathy in genome-wide analysis. J. Am. Soc. Nephrol. 21, 1791-1797 (2010).
26. Gharavi, A. G. et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat. Genet. 43, 321-327 (2011).
27. Yu, X. Q. et al. A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy. Nat. Genet. 44, 178-182 (2012).
28. Yang, C. et al. Genome-wide association study identifies TNFSF13 as a susceptibility gene for IgA in a South Chinese population in smokers. Immunogenetics 64, 747-753 (2012).
29. Cox, S. N. et al. Altered modulation of Wnt-β-catenin and PI3K/Akt pathways in IgA nephropathy. Kidney Int. 78, 396-407 (2010).
30. Preston, G. A. et al. Gene expression profiles of circulating leukocytes correlate with renal disease activity in IgA nephropathy. Kidney Int. 65, 420-430 (2004).
31. Woo, K. T. et al. Urotensin 2 and retinoic acid receptor α (RARA) gene expression in IgA nephropathy. Ann. Acad. Med. Singapore 39, 705-709 (2010).
32. Reich, H. N. et al. A molecular signature of proteinuria in glomerulonephritis. PLoS ONE 5, e13451 (2010).
33. Tokunaga, K. et al. Insulin-like growth factor binding protein-1 levels are increased in patients with IgA nephropathy. Biochem. Biophys. Res. Commun. 399, 144-149 (2010).
34. Flyvbjerg, A. Role of growth hormone, insulin-like growth factors (IGFs) and IGF-binding proteins in the renal complications of diabetes. Kidney Int. Suppl. 60, S12-S19 (1997).
35. Doublier, S. et al. Glomerulosclerosis in mice transgenic for human insulin-like growth factor-binding protein-1. Kidney Int. 57, 2299-2307 (2000).
36. Weber, J. A. et al. The microRNA spectrum in 12 body fluids. Clin. Chem. 56, 1733-1741 (2010).
37. Patnaik, S. K., Mallick, R. & Yendamuri, S. Detection of microRNAs in dried serum blots. Anal. Biochem. 407, 147-149 (2010).
38. Li, J. Y., Yong, T. Y., Michael, M. Z. & Gleadle, J. M. Review: the role of microRNAs in kidney disease. Nephrology (Carlton) 15, 599-608 (2010).
39. Kato, M., Arce, L. & Natarajan, R. MicroRNAs and their role in progressive kidney diseases. Clin. J. Am. Soc. Nephrol. 4, 1255-1266 (2009).
40. Wang, G. et al. Expression of microRNAs in the urinary sediment of patients with IgA nephropathy. Dis. Markers 28, 79-86 (2010).
41. Wang, G. et al. Elevated levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy. Dis. Markers 30, 171-179 (2011).
42. Serino, G., Sallustio, F., Cox, S. N., Pesce, F. & Schena, F. P. Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy. J. Am. Soc. Nephrol. 23, 814-824 (2012).
43. Park, M. R. et al. Establishment of a 2D human urinary proteomic map in IgA nephropathy. Proteomics 6, 1066-1076 (2006).
44. Yokota, H. et al. Absence of increased α1-microglobulin in IgA nephropathy proteinuria. Mol. Cell Proteomics 6, 738-744 (2007).
45. Haubitz, M. et al. Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int. 67, 2313-2320 (2005).
46. He, Q. et al. Urinary proteome analysis by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry with magnetic beads for identifying the pathologic presentation of clinical early IgA nephropathy. J. Biomed. Nanotechnol. 8, 133-139 (2012).
47. Rocchetti, M. T. et al. Urine protein profile of IgA nephropathy patients may predict the response to ACE-inhibitor therapy. Proteomics 8, 206-216 (2008).
48. Maisonneuve, P. et al. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. Am. J. Kidney Dis. 35, 157-165 (2000).
49. Kerjaschki, D. & Farquhar, M. G. The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc. Natl Acad. Sci. USA 79, 5557-5561 (1982).
50. Beck, L. H. Jr et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N. Engl. J. Med. 361, 11-21 (2009).
51. Stanescu, H. C. et al. Risk HLA-DQA1 and PLA2R1 alleles in idiopathic membranous nephropathy. N. Engl. J. Med. 364, 616-626 (2011).
52. Hauser, P. V. et al. Microarray and bioinformatics analysis of gene expression in experimental membranous nephropathy. Nephron Exp. Nephrol. 112, e43-e58 (2009).
53. Ngai, H. H. et al. Serial changes in urinary proteome profile of membranous nephropathy: implications for pathophysiology and biomarker discovery. J. Proteome Res. 5, 3038-3047 (2006).
54. Wang, L. et al. Autophagy can repair endoplasmic reticulum stress damage of the passive Heymann nephritis model as revealed by proteomics analysis. J. Proteomics 75, 3866-3876 (2012).
55. Beck, L. H. Jr et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J. Am. Soc. Nephrol. 22, 1543-1550 (2011).
56. Qin, W. et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J. Am. Soc. Nephrol. 22, 1137-1143 (2011).
57. Cravedi, P., Ruggenenti, P. & Remuzzi, G. Circulating anti-PLA2R autoantibodies to monitor immunological activity in membranous nephropathy. J. Am. Soc. Nephrol. 22, 1400-1402 (2011).
58. Gao, X. et al. Systematic variations associated with renal disease uncovered by parallel metabolomics of urine and serum. BMC Syst. Biol. 6 (Suppl. 1), S14 (2012).
59. Kitiyakara, C., Kopp, J. B. & Eggers, P. Trends in the epidemiology of focal segmental glomerulosclerosis. Semin. Nephrol. 23, 172-182 (2003).
60. D'Agati, V. D., Kaskel, F. J. & Falk, R. J. Focal segmental glomerulosclerosis. N. Engl. J. Med. 365, 2398-2411 (2011).
61. Thomas, D. B. et al. Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int. 69, 920-926 (2006).
62. D'Agati, V. Pathologic classification of focal segmental glomerulosclerosis. Semin. Nephrol. 23, 117-134 (2003).
63. Lowik, M. M., Groenen, P. J., Levtchenko, E. N., Monnens, L. A. & van den Heuvel, L. P. Molecular genetic analysis of podocyte genes in focal segmental glomerulosclerosis-a review. Eur. J. Pediatr. 168, 1291-1304 (2009).
64. Brown, E. J. et al. Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis. Nat. Genet. 42, 72-76 (2010).
65. Boyer, O. et al. INF2 mutations in Charcot-Marie-Tooth disease with glomerulopathy. N. Engl. J. Med. 365, 2377-2388 (2011).
66. Gharavi, A. G. et al. Mapping a locus for susceptibility to HIV-1-associated nephropathy to mouse chromosome 3. Proc. Natl Acad. Sci. USA 101, 2488-2493 (2004).
67. Kopp, J. B. et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat. Genet. 40, 1175-1184 (2008).
68. Kao, W. H. et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat. Genet. 40, 1185-1192 (2008).
69. Ghiggeri, G. M. et al. Genetics, clinical and pathological features of glomerulonephritis associated with mutations of nonmuscle myosin IIA (Fechtner syndrome). Am. J. Kidney Dis. 41, 95-104 (2003).
70. Sekine, T. et al. Patients with Epstein-Fechtner syndromes owing to MYH9 R702 mutations develop progressive proteinuric renal disease. Kidney Int. 78, 207-214 (2010).
71. Genovese, G. et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329, 841-845 (2010).
72. Kanji, Z. et al. Genetic variation in APOL1 associates with younger age at hemodialysis initiation. J. Am. Soc. Nephrol. 22, 2091-2097 (2011).
73. Kopp, J. B. et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J. Am. Soc. Nephrol. 22, 2129-2137 (2011).
74. Johnstone, D. B. et al. APOL1 null alleles from a rural village in India do not correlate with glomerulosclerosis. PLoS ONE 7, e51546 (2012).
75. Hodgin, J. B. et al. A molecular profile of focal segmental glomerulosclerosis from formalin-fixed, paraffin-embedded tissue. Am. J. Pathol. 177, 1674-1686 (2010).
76. Berger, S. I. & Iyengar, R. Role of systems pharmacology in understanding drug adverse events. Wiley Interdiscip. Rev. Syst. Biol. Med. 3, 129-135 (2011).
77. Zhao, S. & Iyengar, R. Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. Annu. Rev. Pharmacol. Toxicol. 52, 505-521 (2012).
78. Jin, Y. et al. A systems approach identifies HIPK2 as a key regulator of kidney fibrosis. Nat. Med. 18, 580-588 (2012).
79. Lamb, J. et al. The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929-1935 (2006).
80. Zhong, Y. et al. Renoprotective effect of combined inhibition of angiotensin-converting enzyme and histone deacetylase. J. Am. Soc. Nephrol. 24, 801-811 (2013).